文献速递术前评估与围术期医学

异体红细胞输血对相关体液和细胞免疫参数的影响:一项前瞻性观察试验

Allogeneic red cell transfusion and its influence on relevant humoral and cellular immunological parameters: A prospective observational trial.
PubMed 文献 · Eur J Anaesthesiol · 2019-01-01

该前瞻性观察研究纳入78例择期重大脊柱手术低危非癌症患者,61例完成分析,分未输血组19例、术中输血组26例和术后第1或2天输血组16例。结果显示,红细胞输血本身未在健康手术患者中引起免疫反应,45项免疫学参数中仅5项相关性小的细胞因子受到轻微且非特异性影响。

要点

  • 低危非癌症脊柱手术患者中,异体红细胞输血未引起明显免疫调节反应。
  • 未输血与输血患者术后感染或血栓发生率差异无统计学意义。
  • 结论不否定已有免疫系统受损患者的输血相关免疫调节现象。

核心结论

  • 数据表明,在原本健康的手术患者中,单纯红细胞输血不会引起免疫反应。
  • 研究结果不普遍否定输血相关免疫调节现象,但该现象主要在免疫系统已受损或手术削弱免疫系统的患者中观察到。

研究设计与样本

  • 前瞻性观察研究,在泰国大学医院骨科手术和麻醉科进行。
  • 纳入78例年龄18至75岁、接受择期重大脊柱手术的低危非癌症患者,61例符合要求并分析。
  • 分析分三组:未输血组19例,术中输血组26例,术后第1或2天输血组16例。
  • 在术前及术后第1、3、5天共四次采集血标本,用流式细胞术和多路ELISA评估免疫细胞和细胞因子。

主要发现

  • 未输血患者术后感染或血栓发生率为5.5%,输血患者为16.6%,差异无统计学意义。
  • 45项免疫学参数中,仅5项相关性小的细胞因子受到显著影响,且影响轻微且非特异性。
  • 无患者发生围术期出血。

临床怎么用

  • 对于低危、非癌症、接受重大脊柱手术的患者,异体红细胞输血本身不应被视作引起明显免疫调节反应的独立因素。
  • 临床决策中仍需结合患者基础免疫状态和手术类型综合评估输血风险。

局限性

  • 研究为观察性设计,样本量有限,仅纳入低危非癌症脊柱手术患者。
  • 结论不能外推至免疫系统已受损或接受其他类型大手术的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is assumed that transfusion of allogeneic red cells is associated with increased peri-operative mortality and morbidity. Also assumed is the theory of transfusion-related immunomodulation. OBJECTIVE: The aim of this study was to investigate the hypothesis that red cell transfusion specifically leads to an immunological response in surgical patients. DESIGN: Prospective observational study. SETTING: Departments of Orthopedic Surgery and Anaesthesia, University Hospital, Thailand. PATIENTS: Low-risk, noncancer patients, aged 18 to 75 years undergoing elective major spine surgery, with and without red cell transfusion therapy. INTERVENTIONS: Blood specimens were withdrawn four times (prior to surgery and on days 1, 3 and 5). MAIN OUTCOME MEASURES: Assessment of immunocompetent cells and cytokines in transfused and nontransfused patients using flow cytometry and multiplex ELISA. RESULTS: From a total of 78 patients, 61 met the requirements and were analysed in three groups: 19 with no transfusion and 26 and 16 transfused intra-operatively and on day 1 or 2, respectively. No patient experienced peri-operative haemorrhage. Postoperative infection or thrombosis occurred in 5.5% of nontransfused patients and 16.6% of transfused patients; the difference was not significant. There was no significant immunomodulatory effect of red cell transfusion: of 45 immunological parameters, only five little-relevant cytokines were significantly affected, although slightly and nonspecifically. CONCLUSION: Our data indicate that red cell transfusion alone does not create an immunological response in otherwise healthy surgical patients. Our findings do not generally contradict the transfusion-related immunomodulation phenomenon, which has, however, primarily been observed in patients with an already weakened or procedure-deteriorated immune system, such as from malignant disease, significant comorbidity, extensive abdominal/thoracic surgery and cardiopulmonary bypass. TRIAL REGISTRATION: The study was registered on 15 May 2014, before enrolment of the first patient, at www.ClinicalTrials.gov, NCT02140216.

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

引用

  1. Suksompong S, Tassaneetrithep B, Ariyawatkul T, et al. Allogeneic red cell transfusion and its influence on relevant humoral and cellular immunological parameters: A prospective observational trial. Eur J Anaesthesiol. 2019. PMID: 31157653. doi:10.1097/EJA.0000000000001027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。